Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema

Open Access
Publisher Website
Google Scholar
Abstract
Intravitreal triamcinolone acetonide has increasingly been used as a treatment for intraocular proliferative, edematous, and neovascular diseases, such as central retinal vein occlusion,1-3 neovascular glaucoma without or with cataract surgery,4,5 proliferative vitreoretinopathy,6 chronic prephthisical ocular hypotony,7 chronic uveitis,8-11 persistent pseudophakic cystoid macular edema,12-14 exudative age-related macular degeneration,15-25 proliferative diabetic retinopathy,26,27 and retinal telangiectasia,28 and in other clinical situations, such as sympathetic ophthalmia.29-33 Recently, intravitreal triamcinolone also has been applied in eyes with diffuse diabetic macular edema,34-41 leading to an increase in visual acuity in some eyes.